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Key messages
What is the key question?
 ► Is there a survival difference between patients 
with stage I non- small cell lung cancer 
(NSCLC) undergoing lobectomy compared with 
stereotactic ablative radiotherapy (SABR)?
What is the bottom line?
 ► There is an early survival benefit for patients 
undergoing SABR, however from 6 months 
onwards, lobectomy has better overall survival. 
The patient pathway for receiving SABR is 
longer than for surgery.
Why read on?
 ► Lobectomy is the treatment of choice for stage 
I NSCLC with SABR offered to people who 
decline lobectomy or in whom lobectomy is 
contraindicated. Trusts and cancer alliances in 
England should look to optimise their patient 
pathways for SABR.
ABSTRACT
Background approximately 15%–20% of all non- 
small cell lung cancer (nsclc) cases present with stage 
i disease. surgical resection traditionally offers the best 
chance of a cure but some patients will not have this 
treatment due to older age, comorbidities or personal 
choice. stereotactic ablative radiotherapy (saBr) has 
become an established curative intent treatment option 
for patients who are not selected for or do not choose 
surgery. The aim of this study is to compare survival at 
90 days, 6 months, 1 year and 2 years for patients who 
received either lobectomy or saBr.
Methods We used data from the 2015 national lung 
cancer audit database and linked with hospital episode 
statistics and the radiotherapy dataset to identify 
patients with nsclc stage ia- iB and performance status 
(Ps) 0–2 who underwent surgery or saBr treatment. We 
assessed the likelihood of death at 90 days, 6 months, 
1 year and 2 year after diagnosis and procedure date to 
observe survival between two patient groups.
Results We identified 2373 patients in our cohort, 476 
of whom had saBr. The median difference between date 
of diagnosis and date of treatment for surgery patients 
was 17 days while for saBr patients it was 73 days. 
increasing age and worsening Ps were associated with 
having saBr rather than surgery. survival between the 
two treatment modalities was similar early on but by 
1- year people who had surgery did better than those 
who had saBr (adjusted Ors 2.12, 95% ci 1.35 to 
2.31). This difference persisted at 2 years and when the 
analysis was restricted to patients aged <80 years and 
with Ps 0 or 1 and stage ia only.
Conclusion Our analysis suggests that patients 
who have lobectomy have a better survival compared 
with saBr patients; however, we found considerable 
delays in patients receiving saBr which may contribute 
to poorer long- term outcomes with this treatment 
option. reducing these delays should be a key focus in 
development and reorganisation of services.
InTRoduCTIon
Non- small cell lung cancer (NSCLC) accounts for 
almost 85% of all pathologically confirmed lung 
cancer cases diagnosed in England. Compared 
with other European and North American coun-
tries, people in England have poor overall survival 
for lung cancer.1 2 This may partly be due to lower 
rates of delivery of potentially curative treatment, 
especially surgical resection in stage I lung cancer.3 
Recent reports from the National Lung Cancer 
Audit (NLCA) 2016 have demonstrated that survival 
figures are improving year on year for England, and 
that resection rates are also increasing.4 However, 
even for patients with early stage and good perfor-
mance status (PS), only 60% ultimately undergo 
surgical resection.5 Approximately 15%–20% of 
people with NSCLC have stage I disease at presen-
tation; increasing this proportion is the goal of 
national early diagnosis programmes and lung 
cancer screening proposals.
Although surgery is the standard of care in early 
lung cancer, stereotactic ablative radiotherapy 
(SABR), a non- invasive external beam radiotherapy 
has become an established treatment option for 
early stage patients with peripheral tumours under 
5 cm, not suitable for, or declining surgery. SABR 
uses hypo- fractionated dose schedules and high 
precision treatment delivery to improve local 
control of disease compared with fractionated 
radical radiotherapy.6 7 Studies have also shown less 
toxicity related to SABR, even in elderly patients, 
with no significant decline in quality of life.8 9
The recent Lung Cancer Clinical Outcome 
Project publication reports an overall 90 days 
survival of 96.3% after surgery for stage I and II, 
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failing to 87.9% after 1 year.4 However, the survival of patients 
who undergo SABR has not been reported in the same popula-
tion. The aim of this study was therefore to evaluate survival 
at different points after treatment for patients who receive 
SABR treatment compared with lobectomy in stage I patients in 
England using the 2015 NLCA database.
MeThodS
databases
National Lung Cancer Audit
The recently validated new NLCA database is a longitudinal 
database that contains data on core cancer and lung specific data 
items. The audit uses anonymised data collected and processed by 
the National Cancer Registration and Analysis Services (NCRAS) 
on all new lung cancer cases submitted by 142 National Health 
Service (NHS) trusts in England. The NLCA was linked with 
Hospital Episode Statistics (HES) inpatient data to provide data 
on any curative/palliative treatment received in secondary care, 
including lung cancer surgery and Office of National Statistics 
for accurate records of date of death.
National radiotherapy dataset
The radiotherapy dataset (RTDS) collects consistent and compa-
rable data in order to provide intelligence for service planning, 
commissioning, clinical practice and research. The RTDS started 
collecting data from April 2009 and all NHS trusts providing 
radiotherapy services are required to return data to Public 
Health England for all activities undertaken on brachytherapy 
and teletherapy machines. Aside from the type and intent of 
radiotherapy given, the RTDS also contains details on date of 
exposure, dose and fraction of each exposure event and trust 
name of where each therapy took place. The RTDS was linked 
with the NLCA and anonymised prior to analysis.
The RTDS does not specify what radiotherapy type was admin-
istered other than the dose and fraction prescribed, and there-
fore to identify SABR doses, the data for the all the prescribed 
dose and prescribed fraction was reviewed by two oncologists 
independently and then statistically assessed for agreement. A 
dose of ≥50 Gray (Gy) delivered in 3–8 fractions was consid-
ered as a SABR dose in our study. We also carried out Cohen’s 
Kappa κ statistics and percentage agreement to assess the level of 
agreement between the two oncologists identifying SABR doses 
in the RTDS database.
Study population and covariates
We conducted a cohort analysis and used data on all English 
patients diagnosed with primary lung cancer defined by the Inter-
national Classification of Disease V.10 (ICD-10) code of C34* 
in 2015, who had a proven or presumed NSCLC. Patients who 
were diagnosed through their death certificate were excluded 
from further analyses. We further restricted our analysis to 
people with stage IA and IB (tumour, node, metastases (TNM) 
V.7 defined by the Union for International Cancer Control) and 
with good PS, that is, PS 0, 1 and 2 as these people are more likely 
to undergo curative treatment. We identified cases of patholog-
ically confirmed NSCLC based on the recorded Systematised 
Nomenclature of Medicine (SNOMED) codes, whereas cases 
without a pathologically confirmed diagnoses, ‘unknown lung 
cancer’ SNOMED codes or clinically confirmed cases were also 
classified as NSCLC. This encompasses around 23%–25% of 
all lung cancer cases annually, and are referred to as ‘presumed’ 
NSCLC cases as majority of the pathologically confirmed cases 
are NSCLC. This is in line with the standard NLCA definition 
of NSCLC.4 Therefore in our cohort, 75% of the people had a 
confirmed pathological diagnosis of NSCLC, while the rest were 
presumed to be NSCLC. Using the HES dataset, we were able to 
obtain data on our cohort’s hospital admissions going back to 
2004 which helped us create a comorbidity score. If the person 
did not have a hospital admission with an ICD-10 code indi-
cating a comorbidity according to the Charlson Index,10 they 
were coded as having no comorbidity.
In addition to treatment data, we extracted data on variables 
including age, sex, PS and stage. Age was calculated at diagnosis 
and grouped into three categories (<65 years, 65–80 years and 
>80 years). PS, a marker to assess patient’s fitness, was classified 
according to the WHO definition and stage of the disease was 
defined using the Union for International Cancer Control defini-
tion (TNM V.7), both are recorded in the NLCA. We identified the 
type of surgery a patient had from NLCA and HES using Office of 
Population Census and Survey Classification of Intervention V.4 
codes. If there was more than one lung surgery recorded, the most 
extensive one was considered. We only included patients who had 
either lobectomy or bilobectomy (E54.2, E54.3). All treatments 
recorded 6 months after diagnosis were excluded on the basis that 
they may not be related to lung cancer.
Statistical analysis
All data and statistical analysis were performed using STATA 
V.15. First we conducted a logistic regression analysis to assess 
association between patient features and likelihood of receiving 
SABR rather than surgical resection. For our main analyses the 
endpoints were the likelihood of death at 90 days, 6 months, 
1 year, 2 years and overall survival, defined as the time interval 
between (1) first date of treatment (either SABR or surgery) and 
date of death from any cause and (2) time difference between 
date of diagnosis and date of death—to account for the lag time 
between treatment decision and start of SABR for cases where 
surgery was initially considered but not received. We used logistic 
regression analysis to compare survival odds at each specified 
time points and Cox regression to assess overall survival differ-
ence. Log minus log and Schoenfeld tests were performed to 
check for proportional hazard assumptions and Kaplan- Meier 
curves estimating survival difference between two groups from 
time of procedure and time of diagnosis. As a sensitivity analysis 
to limit the analysis to very fit patients, we also conducted similar 
analysis on stage IA patients only, excluding patients over the age 
of 80 years and those with poor PS (PS=2)—patient character-
istics that are clinically strongly associated with receiving SABR 
over lobectomy. We present adjusted ORs that were adjusted for 
sex, age, PS, stage, comorbidity score, socioeconomic status, lung 
cancer laterality and pathological confirmation of the diagnosis. 
All logistic regression analyses were also assessed with 99% CI 
limits to remove bias by multiple comparisons. Kaplan- Meier 
(KM) curves for survival by treatment groups and restricted to 
age <80, stage IA and PS 0–1 were plotted.
ReSuLTS
We identified 2373 English patients diagnosed between 1 January 
2015 and 31 December 2015 from the linked NLCA dataset 
that met our inclusion criteria (NSCLC, PS 0–2 and stage IA/IB). 
The median follow- up length was 2.14 years (IQR 1.85–2.43 
years). Baseline patient characteristics are presented in table 1. 
Fifty- three per cent of our cohort were females (53%) and more 
than three- fifths of the cohort were aged between 65 and 80 
years (62%). 40% had PS 0, 45% had PS 1 and the majority 
(60%) of the cohort had stage IA NSCLC. Patients treated with 
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Table 1 Descriptive statistics comparing patient features (n=2373)
Surgery (n=1897) SABR (n=476)
P valueno. % no. %
Sex
  Female 1007 53 252 53
  Male 890 47 224 47 0.95
Age
  <65 569 30 52 11
  65–80 1193 63 277 58
  >80 135 7 147 31 <0.001
Performance status
  0 894 47 63 13
  1 852 45 212 45
  2 151 8 201 42 <0.001
Stage
  IA 1084 57 348 73
  IB 813 43 128 27 <0.001
Charlson Index
  0 716 38 178 37
  1 498 26 82 17
  2–3 447 24 121 25
  4+ 236 12 95 20 <0.001
Socioeconomic status
  1 300 16 65 14
  2 351 18 84 18
  3 368 19 92 19
  4 412 22 115 24
  5 (most deprived) 466 25 120 25 0.66
Pathology confirmed diagnosis
  No 12 1 228 48
  Yes 1885 99 248 52 <0.001
Laterality
  Left 749 39 192 40
  Right 1148 61 284 60 0.73
SABR, stereotactic ablative radiotherapy.
Table 2 Likelihood of receiving SABR compared with surgery based 












  Female 1259 20 1 1
  Male 1114 20 1.00 (0.82 to 1.23) 0.79 (0.58 to 1.06)
Age
  <65 621 8 1 1
  65–80 1470 19 2.54 (1.85 to 3.47) 2.60 (1.68 to 4.03)†
  >80 282 52 11.9 (8.24 to 17.2) 12.4 (7.45 to 20.9)†
Performance status
  0 957 7 1 1
  1 1064 20 3.53 (2.62 to 4.74) 2.69 (1.83 to 3.94)†
  2 352 57 18.8 (13.5 to 26.3) 14.5 (9.40 to 22.6)†
Stage
  IA 1432 24 1 1
  IB 941 14 0.49 (0.39 to 0.61) 0.48 (0.35 to 0.66)†
Charlson Index
  0 894 20 1 1
  1 580 14 0.66 (0.49 to 0.88) 0.68 (0.45 to 1.02)
  2–3 568 21 1.08 (0.84 to 1.41) 1.02 (0.70 to 1.50)
  4+ 331 29 1.61 (1.21 to 2.16) 1.14 (0.74 to 1.76)
Socioeconomic status
  1 365 15 1 1
  2 435 18 1.10 (0.77 to 1.58) 0.88 (0.53 to 1.47)
  3 460 19 1.15 (0.81 to 1.64) 0.85 (0.51 to 1.41)
  4 527 22 1.28 (0.91 to 1.80) 1.17 (0.72 to 1.90)
  5 (most 
deprived)
586 25 1.18 (0.85 to 1.66) 0.89 (0.54 to 1.45)
Pathology confirmed diagnosis
  No 240 10 1 1





  Left 941 40 1 1
  Right 1432 60 0.96 (0.78 to 1.18) 1.13 (0.84 to 1.52)
*Adjusted for all the variables in the table.
†Significant at 99% CIs.
SABR, stereotactic ablative radiotherapy.
lobectomy had better comorbidity score (Charlson Index 0 or 1) 
than those undergoing SABR. Using the Cohen’s Kappa statistics 
and percentage agreement, the results from the two oncologists 
agreed on 99% of the patient radiotherapy doses in the RTDS 
with a kappa coefficient of 0.993 and we identified 476 patients 
who received SABR while 1897 had surgery.
We used logistic regression analysis to identify patient features 
most strongly associated with treatment and these are presented 
in table 2. There was no association seen with type of treat-
ment received and sex and laterality; however, increasing age 
was associated with a higher likelihood of having undergone 
SABR compared with patients aged less than 65 years (age 80 
and above OR 12.4, 95% CI 7.45 to 20.9). Patients with stage 
IB were 52% less likely to have SABR compared with patients 
with stage IA lung cancer (OR 0.48, 95% CI 0.35 to 0.66). A 
strong association was also seen with increasing PS and likeli-
hood of having SABR (PS 2 OR 14.5, 95% CI 9.40 to 22.6). 
This association was still present when patients with missing PS 
were excluded from the analysis. While in our univariate analysis 
we saw an association between patients undergoing SABR with 
a comorbidity index of 4 or more, this was not observed when 
adjusted for other patient features in table 2.
Pathway from diagnosis to treatment
The median difference between date of diagnosis and date of 
treatment for surgery patients was 17 days (IQR 1–44) and 73 
days (IQR 56–103) for patients who underwent SABR. The 
median time difference from diagnosis to treatment in biopsied 
SABR patients was 70 days, 10 days less than SABR patients 
who were not biopsy confirmed. We also considered the time 
difference between start of treatment and the final pretreat-
ment multi- disciplinary teams (MDT) discussion date which 
still showed a difference of almost a month between SABR and 
surgery (time difference between MDT and surgery =34 days, 
MDT and SABR =61 days).
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Figure 1 Unadjusted Kaplan- Meier estimates from the date of 
procedure and number of patients at risk of death at 6 months interval.
Figure 2 Adjusted Kaplan- Meier estimates from the date of procedure 
(adjusted for sex, age, performance status, stage, Charlson Index, 
socioeconomic status, pathology confirmation and lung cancer laterality.
overall survival
In the first 6 months postprocedure, there were 35 deaths from 
any cause in the lobectomy group and 21 deaths in SABR group. 
This doubled in the next 6 months with an additional 52 deaths 
from any cause in the lobectomy group and 48 deaths in the 
SABR group. For our Cox regression analyses the proportional 
hazard assumptions were not met, and for this reason we are 
not reporting an overall HR but have included the unadjusted 
and adjusted Kaplan- Meier survival curves (figures 1 and 2). 
Our Kaplan- Meier plots show good overall survival for people 
undergoing both SABR and lobectomy. The curves are similar 
for lobectomy and SABR for the first 6 months, but thereafter 
lobectomy seems to have a better survival.
Likelihood of death from date of treatment
The results of logistic regression analysis conducted from the date of 
either lobectomy or SABR procedure are presented in table 3. Male 
gender, increasing age, worse PS, advance stage, comorbidity and 
cancer laterality were not associated with survival.
We found no evidence of a difference in survival between 
the treatment modalities in the first 180 days after treatment. 
However, by 1 year, the likelihood of death from any cause for 
SABR patients was higher than those having surgery (adjusted OR 
2.12, 95% CI 1.35 to 3.31). This difference persisted at 2 years 
where the ORs for death from any cause for SABR compared with 
lobectomy was 2.20 (95% CI 1.56 to 3.09–99% CI 1.40 to 3.45) 
(see online supplementary appendix 1 for tables with 99% CI). 
In addition we found that in our sensitivity analyses on stage IA 
patients only, excluding patients over the age of 80 years with poor 
PS (PS≥2) (online supplementary table S1), the survival benefit of 
surgery vs SABR persisted at 1 year and 2 years.
Likelihood of death from date of diagnosis
We conducted a separate logistic regression analysis from the 
date of diagnosis of lung cancer until death, presented in table 4. 
The difference in the likelihood of death was not observed until 
after 1 year from diagnosis (2 years ORs 1.89, 95% CI 1.33 to 
2.69, 99% CI 1.19 to 3.01). Male gender, older age, worsening 
PS, advance stage lung cancer and being from the most deprived 
socioeconomical group were associated with a higher likelihood 
of death at 95% CI but only PS 2 and stage IB were significant at 
99% CI at 1 year (see online supplementary appendix table). PS 
2, stage IA and IB, most deprived socioeconomic status and male 
gender were significant at 99% CI at 2 years. When the results 
were restricted to patients aged <80 year and with PS 0 or 1 
and stage IA, SABR patients had an overall poor survival which 
was only significant at 5% (p value 0.035) (online supplementary 
table S2). None of the patient features were significantly associ-
ated with increased likelihood of death at 1 year at 99% CI (most 
deprived socioeconomical status significant at 95% CI).
dISCuSSIon
Main findings
The present study is the first to use English registry data to look 
at outcomes for stage I NSCLC patients treated with either lobec-
tomy or SABR. Real world data is especially important because 
randomised trials comparing lobectomy to SABR closed due to 
poor recruitment.11 Similar to other registry studies, this anal-
ysis shows long- term overall survival benefit for patients treated 
with lobectomy, an association also present when the analysis was 
restricted by exclusion of older patients with PS 2 and stage IB. 
Lobectomy remains the treatment of choice for stage I NSCLC in 
the new National Institute for Health and Care Excellence (NICE) 
guidelines.12
Patient features including age, PS, comorbidity and stage were 
very strongly associated with the type of treatment received and 
contribute to the better survival for patients undergoing lobec-
tomy compared with SABR similar to results from published 
meta- analysis.13 Our result shows, that the patients undergoing 
SABR were significantly more likely to be older, have poor PS and 
have more comorbidities. This study also supports NICE recom-
mendations that SABR should be offered as the curative intent 
treatment of choice to stage I NSCLC patients who are medically 
inoperable due to comorbidities or who decline surgery. Another 
association that remained in our sensitivity analysis was the 
overall increased likelihood of death in the most deprived socio-
economic group compared with others even after taking into 
account multiple patient and tumour features. We believe the 
increased comorbidity associated with a higher smoking preva-
lence in this groups14 could account for the poor outcome in this 
group. There is a possibility that we may have underestimated 
comorbidity. However, studies comparing comorbidity records 
in primary care data with secondary care data in England have 
shown that although HES missed a few comorbid conditions, life 
changing comorbidity, which is more likely to require hospital 
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Table 3 Regression analysis from date of procedure till death at 90 days, 6 months, 1 year and overall
Total number of 
patients
Adjusted oR at 90 days 
after procedure (95% CI)*
Adjusted oR at 180 
days after procedure 
(95% CI)*
Adjusted oR at 365 
days after procedure 
(95% CI)*
Adjusted oR at 730 
days after procedure 
(95% CI)*
Type of Treatment
  Lobectomy 1897 1 1 1 1
  SABR 476 0.63 (0.22 to 1.83) 0.88 (0.42 to 1.80) 2.12 (1.35 to 3.31)†‡ 2.20 (1.56 to 3.09)†‡
Sex
  Female 1259 1 1 1 1
  Male 1114 1.50 (0.84 to 2.67) 1.32 (0.85 to 2.06) 1.38 (1.01 to 1.88) 1.54 (1.22 to 1.94)†‡
Age
  <65 621 1 1 1 1
  65–80 1470 1.76 (0.79 to 3.92) 1.64 (0.87 to 3.07) 1.34 (0.89 to 2.03) 1.09 (0.81 to 1.46)
  >80 282 2.57 (0.88 to 7.49) 2.54 (1.14 to 5.64) 1.74 (1.00 to 3.00) 1.76 (1.18 to 2.62)†
Performance status
  0 957 1 1 1 1
  1 1064 1.63 (0.84 to 3.18) 1.77 (1.03 to 3.04) 1.38 (0.95 to 2.02) 1.46 (1.10 to 1.93)†‡
  2 352 1.64 (0.62 to 4.28) 2.55 (1.27 to 5.11)† 1.85 (1.15 to 2.98) 2.34 (1.64 to 3.33)†
Stage
  IA 1432 1 1 1 1
  IB 941 2.06 (1.15 to 3.72) 2.07 (1.32 to 3.25)† 1.85 (1.35 to 2.54)† 2.03 (1.60 to 2.58)†
Charlson Index
  0 894 1 1 1 1
  1 580 1.12 (0.54 to 2.32) 0.97 (0.55 to 1.70) 1.22 (0.81 to 1.83) 1.37 (1.01 to 1.87)
  2–3 568 0.94 (0.44 to 2.03) 0.84 (0.47 to 1.51) 0.94 (0.62 to 1.44) 1.28 (0.94 to 1.75)
  4+ 331 0.98 (0.39 to 2.46) 0.89 (0.44 to 1.79) 1.33 (0.84 to 2.10) 1.78 (1.25 to 2.51)†
Socioeconomic status
  1 365 1 1 1 1
  2 435 2.05 (0.63 to 6.66) 1.23 (0.57 to 2.61) 1.37 (0.76 to 2.46) 1.11 (0.72 to 1.71)
  3 460 1.42 (0.41 to 4.94) 0.87 (0.39 to 1.96) 1.29 (0.71 to 2.32) 1.16 (0.76 to 1.77)
  4 527 2.92 (0.96 to 8.93) 1.40 (0.68 to 2.88) 1.68 (0.96 to 2.92) 1.49 (1.00 to 2.24)
  5 (most deprived) 586 2.14 (0.68 to 6.76) 0.98 (0.46 to 2.08) 1.72 (0.99 to 2.97) 1.72 (1.16 to 2.55)†‡
Pathology confirmed diagnosis
  No 240 1 1 1 1
  Yes 2133 1.06 (0.28 to 4.04) 0.92 (0.39 to 2.15) 1.05 (0.63 to 1.75) 1.05 (0.70 to 1.57)
Laterality
  Left 941 1 1 1 1
  Right 1432 1.11 (0.62 to 1.99) 0.93 (0.60 to 1.45) 1.04 (0.76 to 1.43) 0.93 (0.74 to 1.18)
*Adjusted for all the variables in the table.
†Significant at 99% CI.
‡Significant in restricted analysis (restricted analysis excluded patients aged <80 years, performance status 2 and stage IB).
SABR, stereotactic ablative radiotherapy.
admission, was better recorded in HES.15 Therefore, with better 
recording of life threatening and life limiting conditions in HES, 
it would not have influenced our results much.
Results from studies comparing lobectomy with SABR have 
failed to reach consensus with some studies favouring early survival 
and comparable short and overall survival for patients undergoing 
SABR compared with surgical resection9 16–18 while others have 
shown higher overall survival for surgery.19 However, a meta- 
analysis of 12 studies by Deng et al20 showed that SABR was associ-
ated with a significantly lower 3- year overall survival (relative risk 
of death (surgery/SABR)=0.78). One of the reasons for the lack 
of consensus may be that different proportions of different oper-
ations form the comparison with SABR; these may be lobectomy, 
sub lobar resections or even pneumonectomy. Another major 
factor is undoubtedly the difficulty with adequately controlling for 
frailty in the SABR group. Despite our best attempts to control 
for this in our study, there may still be some residual confounding 
due to frailty. Our study shows similar results to study by Puri et 
al19 using the American National Cancer Database in which they 
conclude that patients with surgery have longer overall survival 
than those who undergo SABR.
An unexpected finding in this study was a large time differ-
ence from diagnosis to treatment between patients who have 
surgery and SABR and there may be a number of reasons for 
this, reflecting everyday practice in England. One of the factors 
may be lag time for offering SABR to patients initially thought 
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Table 4 Regression analysis from date of diagnosis till death at 90 days, 6 months, 1 year and overall
Total number of 
patients
Adjusted oR at 90 days 
after procedure (95% CI)*
Adjusted oR at 180 
days after procedure 
(95% CI)*
Adjusted oR at 365 
days after procedure 
(95% CI)*
Adjusted oR at 730 
days after procedure 
(95% CI)*
Type of treatment
  Lobectomy 1897 1 1 1 1
  SABR 476 0.26 (0.03 to 2.04) 0.29 (0.09 to 0.94) 1.25 (0.74 to 2.08) 1.89 (1.33 to 2.69)†‡
Sex
  Female 1259 1 1 1 1
  Male 1114 1.40 (0.70 to 2.80) 1.46 (0.85 to 2.49) 1.46 (1.05 to 2.04) 1.47 (1.16 to 1.86)†‡
Age
  <65 621 1 1 1 1
  65–80 1470 2.27 (0.84 to 6.08) 1.74 (0.84 to 3.58) 1.58 (1.00 to 2.49) 1.09 (0.81 to 1.47)
  >80 282 2.95 (0.73 to 11.9) 2.89 (1.08 to 7.72) 2.11 (1.16 to 3.86) 1.59 (1.05 to 2.39)
Performance status
  0 957 1 1 1 1
  1 1064 1.35 (0.66 to 2.77) 1.70 (0.91 to 3.17) 1.54 (1.03 to 2.31) 1.52 (1.14 to 2.01)†‡
  2 352 0.30 (0.03 to 2.45) 2.62 (1.14 to 6.05) 2.22 (1.32 to 3.71)† 2.35 (1.64 to 3.38)†
Stage
  IA 1432 1 1 1 1
  IB 941 2.15 (1.06 to 4.35) 2.05 (1.19 to 3.54)† 1.93 (1.37 to 2.70)† 2.00 (1.57 to 2.55)†
Charlson Index
  0 894 1 1 1 1
  1 580 1.18 (0.49 to 2.84) 0.91 (0.45 to 1.83) 1.22 (0.79 to 1.88) 1.32 (0.97 to 1.81)
  2–3 568 1.23 (0.50 to 2.98) 0.95 (0.47 to 1.90) 0.90 (0.57 to 1.42) 1.17 (0.85 to 1.60)
  4+ 331 0.99 (0.30 to 3.26) 1.05 (0.46 to 2.40) 1.42 (0.87 to 2.31) 1.67 (1.17 to 2.37)†
Socioeconomic status
  1 365 1 1 1 1
  2 435 1.96 (0.50 to 7.70) 1.82 (0.62 to 5.35) 1.47 (0.80 to 2.69) 1.19 (0.77 to 1.85)
  3 460 1.41 (0.33 to 6.03) 1.50 (0.49 to 4.57) 1.01 (0.53 to 1.92) 1.20 (0.77 to 1.85)
  4 527 2.60 (0.70 to 9.67) 2.39 (0.85 to 6.68) 1.51 (0.84 to 2.72) 1.53 (1.01 to 2.31)
  5 (most deprived) 586 2.47 (0.66 to 9.26) 2.41 (0.86 to 6.71) 1.62 (0.91 to 2.89) 1.78 (1.19 to 2.67)†‡
Pathology confirmed diagnosis
  No 240 1 1 1 1
  Yes 2133 – 1.78 (0.32 to 9.68) 0.98 (0.53 to 1.79) 0.92 (0.61 to 1.39)
Laterality
  Left 941 1 1 1 1
  Right 1432 1.01 (0.51 to 2.03) 0.91 (0.53 to 1.55) 1.11 (0.79 to 1.57) 0.94 (0.74 to 1.19)
*Adjusted for all the variables in the table.
†Significant at 99% CI.
‡Significant in restricted analysis (restricted analysis excluded patients aged <80 years, performance status 2 and stage IB).
SABR, stereotactic ablative radiotherapy.
to be medically operable but subsequently found to be border-
line or too high risk on further assessment. Second, the NLCA 
definition of ‘date of diagnosis’ prioritises date of pathology but 
for patients who do not have pathology (48% of SABR patients), 
the date of diagnosis would be the first date of CT or CT- PET 
imaging, which typically occurs earlier in the pathway. Medi-
cally inoperable, frailer SABR patients may have had several 
CTs demonstrating growth of an unbiopsied pulmonary nodule 
before proceeding to PET- CT scan and then delivering SABR.21 
This timeline should improve as English hospitals work towards 
implementing the National Optimal Lung Cancer Pathway and 
while SABR may still be deliverable, the new TNM8 staging 
reflects that even small increases in the size of stage I lung cancers 
influences long- term outcome.22 23 Conversely, the low patho-
logical confirmation rates in SABR patients (52%) compared 
with surgical patients (99%) may positively influence survival 
for patients, as some may not have lung cancer, although other 
studies have not shown this to be the case.24 Finally, variation in 
health service resources may also be a factor as SABR was only 
available in 17 English radiotherapy centres in 2015 and not all 
lung MDTs had access to a SABR oncologist, requiring tertiary 
referral for consideration of this treatment. Increasing access 
to lung SABR across the country by commissioning lung SABR 
delivery in more radiotherapy centres may help address this and 
in addition, may allow more older, frailer stage I patients who 
currently receive no treatment at all, easier access to SABR.
6 Khakwani A, et al. Thorax 2019;0:1–7. doi:10.1136/thoraxjnl-2018-212493
Lung cancer
Limitations to our study include the lack of adjustment for 
lung function, tumour location, size and comorbidities which 
have not led to a hospital admission but may have influenced 
treatment selection. The NCRAS and NLCA databases either do 
not collect data on these items or have poor data completeness. 
We were also unable to identify and include sublobar resections 
in the surgical group or differentiate the surgery category of 
‘lobectomy’ into types including open lobectomy, video assisted 
thoracoscopic surgery (VATS) or robotic, which may have under-
estimated mortality if reports of mortality rate of surgery being 
better with VATS are confirmed.25
Another important limitation is the lack of nationally collected 
data on disease specific survival and recurrence. Although our data 
shows that patients undergoing SABR are more likely to die in 
the months after treatment, we cannot know what proportion of 
deaths in each group occur from lung cancer or from unrelated 
conditions, although the fact there was no increased risk of death 
at early time points would suggest the risk of treatment- related 
death is low in both groups. In view of the fact that SABR patients 
are generally older and of poorer PS, their risk of non- cancer 
related death is likely to be substantial as reported in a contempo-
rary SABR cohort within the CHISEL trial where there were more 
deaths from non- cancer related causes than from lung cancer itself 
in the months following treatment.7
Clinical relevance
This study has identified an overall survival difference in stage I 
NSCLC patients undergoing lobectomy versus SABR in routinely 
collected real world data and supports the recent NICE guidance 
of recommending lobectomy as treatment of choice with SABR 
or sublobar resection offered for people who decline lobectomy 
or in whom it is contraindicated. It also identified delays in the 
patient pathway for SABR compared with lobectomy which 
should be addressed nationally.
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